
    
      The Primary Hypothesis is that such a study will be feasible as defined by subject adherence
      to study medication and study procedures and avoidance of other cannabinoid containing
      substances during the trial period as well as by ability to mask subjects and investigators
      to treatment assignment

      Secondary hypotheses are:

      Dronabinol will:

      Reduce patient-reported pain interference Reduce patient-reported pain scores and change
      patient-reported pain quality. Reduce use of opioid pain medications. Improve
      patient-reported stiffness, nausea and vomiting, sleep, mood, anxiety, and social
      functioning.

      Reduce markers of inflammation.
    
  